यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agents antinéoplasiques - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

कनाडा - फ़्रेंच - Health Canada

teva canada limited - topotécane (chlorhydrate de topotécan) - solution - 1mg - topotécane (chlorhydrate de topotécan) 1mg - antineoplastic agents

कनाडा - फ़्रेंच - Health Canada

teva canada limited - topotécane (chlorhydrate de topotécan) - poudre pour solution - 1mg - topotécane (chlorhydrate de topotécan) 1mg - antineoplastic agents

कनाडा - फ़्रेंच - Health Canada

teva canada limited - topotécane (chlorhydrate de topotécan) - poudre pour solution - 4mg - topotécane (chlorhydrate de topotécan) 4mg - antineoplastic agents

फ़्रांस - फ़्रेंच - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

mylan sas - topotécane - solution - 1 mg - composition pour 1 ml de solution > topotécane : 1 mg . sous forme de : chlorhydrate de topotécane - autre agent antineoplasique

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

grunenthal sa-nv - buprénorphine 20 mg/25 cm² - dispositif transdermique - 35 µg/h - buprénorphine 20 mg - buprenorphine

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

grunenthal sa-nv - buprénorphine 30 mg/37,5 cm² - dispositif transdermique - 52,5 µg/h - buprénorphine 30 mg - buprenorphine

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

grunenthal sa-nv - buprénorphine 40 /50 40 mg/50 cm² (nominal release speed: 70 µg/h (96 h)) - dispositif transdermique - 70 µg/h - buprénorphine 40 mg - buprenorphine

कैमरून - फ़्रेंच - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

cotec - dihydroartemisinine/phosphate de pipÉraquine - comprimé sécable - 40mg+320mg

फ़्रांस - फ़्रेंच - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - topotécane - solution - 1 mg - composition pour 1 ml de solution à diluer pour perfusion > topotécane : 1 mg . sous forme de : chlorhydrate de topotécane - autre agent antineoplasique